Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | FKBP1A | P62942 | 6/20 | 0.48 |
| ▸ | PEPD | P12955 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23217918 | 0.90 | RAB9A (0.50) | POLBRAB9AFKBP1AALDH1A1SMN1; SMN2 | |
| SCHEMBL20351263 | 0.89 | RAB9A (0.47) | POLBRAB9AFKBP1APEPDALDH1A1 | |
| SCHEMBL20351315 | 0.89 | RAB9A (0.47) | POLBRAB9AFKBP1APEPDALDH1A1 | |
| SCHEMBL3009794 | 0.87 | FKBP1A (0.54) | POLBRAB9AFKBP1APEPDALDH1A1 | |
| SCHEMBL3009795 | 0.87 | FKBP1A (0.54) | POLBRAB9AFKBP1APEPDALDH1A1 | |
| SCHEMBL5499151 | 0.87 | FKBP1A (0.54) | POLBRAB9AFKBP1APEPDALDH1A1 | |
| SCHEMBL3231642 | 0.84 | FKBP1A (0.51) | POLBRAB9AFKBP1APEPDALDH1A1 | |
| SCHEMBL20123372 | 0.84 | POLB (0.50) | POLBRAB9AFKBP1APEPDALDH1A1 | |
| SCHEMBL9546469 | 0.83 | POLB (0.58) | POLBRAB9AFKBP1APEPDALDH1A1 | |
| SCHEMBL30599979 | 0.83 | POLB (0.58) | POLBRAB9AFKBP1APEPDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215030-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250179103-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | RECLUDIX PHARMA, INC. | 2025-06-05 | — | — | US | disclosed |
| EP-4499656-A1 | STAT MODULATORS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-119301127-A | 6-Oxo-decahydro pyrrolo [1,2-a ] [1,5] diazocine and 6-oxo-decahydro-4H-pyrrolo [2,1-d ] [1,5] thiaazacine derivatives as modulators of STAT3 and STAT6 for the treatment of cancer and inflammatory conditions | 瑞克鲁迪克斯制药股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-119183453-A | STAT modulators and uses thereof | 瑞克鲁迪克斯制药股份有限公司 | 2024-12-24 | — | — | CN | disclosed |
| WO-2023192960-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023164680-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | RECLUDIX PHARMA, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| US-8536336-B2 | Prodrug compounds useful as cannabinoid ligands | ABBVIE INC. (US) | 2013-09-17 | — | — | US | disclosed |
| WO-2011075522-A1 | PRODRUG COMPOUNDS USEFUL AS CANNABINOID LIGANDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20110144165-A1 | PRODRUG COMPOUNDS USEFUL AS CANNABINOID LIGANDS | ABBOTT LABORATORIES (US) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179103-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | STAT6, STAT3, STAT1 | POLB 4310/4885RAB9A 3546/4885FKBP1A 1523/4885 |
| US-20110144165-A1 | PRODRUG COMPOUNDS USEFUL AS CANNABINOID LIGANDS | CNR2, CNR1, OPRL1 | POLB 3056/4885RAB9A 704/4885FKBP1A 768/4885 |
| US-20250215030-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | POLB 4657/4885RAB9A 2889/4885FKBP1A 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.